156 related articles for article (PubMed ID: 16301122)
1. Pathologic findings and therapeutic outcome of desperation post-chemotherapy retroperitoneal lymph node dissection in advanced germ cell cancer.
Beck SD; Foster RS; Bihrle R; Einhorn LH; Donohue JP
Urol Oncol; 2005; 23(6):423-30. PubMed ID: 16301122
[TBL] [Abstract][Full Text] [Related]
2. Post chemotherapy RPLND in patients with elevated markers: current concepts and clinical outcome.
Beck SD; Foster RS; Bihrle R; Einhorn LH; Donohue JP
Urol Clin North Am; 2007 May; 34(2):219-25; abstract ix-x. PubMed ID: 17484926
[TBL] [Abstract][Full Text] [Related]
3. Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection.
Beck SD; Foster RS; Bihrle R; Einhorn LH; Donohue JP
J Clin Oncol; 2005 Sep; 23(25):6149-56. PubMed ID: 16135481
[TBL] [Abstract][Full Text] [Related]
4. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome.
Stephenson AJ; Bosl GJ; Motzer RJ; Kattan MW; Stasi J; Bajorin DF; Sheinfeld J
J Clin Oncol; 2005 Apr; 23(12):2781-8. PubMed ID: 15837993
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant chemotherapy for stage II nonseminomatous germ cell tumors.
Kondagunta GV; Motzer RJ
Urol Clin North Am; 2007 May; 34(2):179-85; abstract ix. PubMed ID: 17484923
[TBL] [Abstract][Full Text] [Related]
6. Desperation Postchemotherapy Retroperitoneal Lymph Node Dissection for Metastatic Germ Cell Tumors.
Carver BS
Urol Clin North Am; 2015 Aug; 42(3):343-6. PubMed ID: 26216821
[TBL] [Abstract][Full Text] [Related]
7. Primary retroperitoneal lymph node dissection in patients with clinical stage IS testis cancer.
Williams SB; Steele GS; Richie JP
J Urol; 2009 Dec; 182(6):2716-20. PubMed ID: 19836777
[TBL] [Abstract][Full Text] [Related]
8. Adjunctive nephrectomy at post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer.
Stephenson AJ; Tal R; Sheinfeld J
J Urol; 2006 Nov; 176(5):1996-9; discussion 1999. PubMed ID: 17070234
[TBL] [Abstract][Full Text] [Related]
9. [Delayed retroperitoneal lymph node excision in treatment of advanced non-seminomatous germinal cell tumors. I. Intraoperative findings in marker converted tumor].
Otto T; Goepel M; Seeber S; Rübben H
Urologe A; 1993 May; 32(3):189-93. PubMed ID: 7685554
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
[TBL] [Abstract][Full Text] [Related]
11. Laparoscopic retroperitoneal lymph node dissection: does it still have a role in the management of clinical stage I nonseminomatous testis cancer? A European perspective.
Rassweiler JJ; Scheitlin W; Heidenreich A; Laguna MP; Janetschek G
Eur Urol; 2008 Nov; 54(5):1004-15. PubMed ID: 18722704
[TBL] [Abstract][Full Text] [Related]
12. Factors that influence the results of salvage surgery in patients with chemorefractory germ cell carcinomas with elevated tumor markers.
Habuchi T; Kamoto T; Hara I; Kawai K; Nakao M; Nonomura N; Kobayashi T; Ogawa O; Kamidono S; Akaza H; Okuyama A; Kato T; Miki T
Cancer; 2003 Oct; 98(8):1635-42. PubMed ID: 14534879
[TBL] [Abstract][Full Text] [Related]
13. A 25-year single institution experience with surgery for primary mediastinal nonseminomatous germ cell tumors.
Kesler KA; Rieger KM; Hammoud ZT; Kruter LE; Perkins SM; Turrentine MW; Schneider BP; Einhorn LH; Brown JW
Ann Thorac Surg; 2008 Feb; 85(2):371-8. PubMed ID: 18222228
[TBL] [Abstract][Full Text] [Related]
14. Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor?
Beck SD; Foster RS; Bihrle R; Donohue JP; Einhorn LH
Cancer; 2007 Sep; 110(6):1235-40. PubMed ID: 17665498
[TBL] [Abstract][Full Text] [Related]
15. Retroperitoneal lymph node dissection in patients with high risk testicular cancer.
Williams SB; McDermott DW; Dock W; Bahnson E; Berry AM; Steele GS; Richie JP
J Urol; 2009 May; 181(5):2097-101; discussion 2101-2. PubMed ID: 19286227
[TBL] [Abstract][Full Text] [Related]
16. Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer.
Stephenson AJ; Bosl GJ; Motzer RJ; Bajorin DF; Stasi JP; Sheinfeld J
J Clin Oncol; 2007 Dec; 25(35):5597-602. PubMed ID: 18065732
[TBL] [Abstract][Full Text] [Related]
17. The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor.
Dash A; Carver BS; Stasi J; Bajorin DF; Motzer RJ; Bosl GJ; Sheinfeld J
Cancer; 2008 Feb; 112(4):800-5. PubMed ID: 18172902
[TBL] [Abstract][Full Text] [Related]
18. Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissection.
Spiess PE; Brown GA; Liu P; Tu SM; Tannir NM; Evans JG; Kamat AM; Kassouf W; Pisters LL
J Urol; 2007 Jan; 177(1):131-8. PubMed ID: 17162023
[TBL] [Abstract][Full Text] [Related]
19. Does the presence of extranodal extension in pathological stage B1 nonseminomatous germ cell tumor necessitate adjuvant chemotherapy?
Beck SD; Cheng L; Bihrle R; Donohue JP; Foster RS
J Urol; 2007 Mar; 177(3):944-6. PubMed ID: 17296383
[TBL] [Abstract][Full Text] [Related]
20. Significance of primary tumor size and preorchiectomy serum tumor marker level in predicting pathologic stage at retroperitoneal lymph node dissection in clinical Stage A nonseminomatous germ cell tumors.
Beck SD; Foster RS; Bihrle R; Donohue JP
Urology; 2007 Mar; 69(3):557-9. PubMed ID: 17382165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
